ã«ã«ããŒæ ªåŒäŒç€Ÿã¯2025幎4æ25æ¥ïŒéïŒãåçåŽåçäŒèŠå®€ã«ãŠãé 倩å 倧åŠãšã®å
±åç ç©¶ãè¡æ¶²éææ£è
ã«ããããã«ãŒãå
¥ãã°ã©ããŒã©æåãè¡å§äœäžããã³è
žå
现èå¢ã«åãŒã圱é¿ãã«é¢ããç ç©¶çµæãçºè¡šãããåœæ¥ã¯ãé 倩å 倧åŠå»åŠéš è
èå
ç§åŠè¬åº§ äžç° èª äº éåžžå€è¬åž«ããããã«ãŒãå
¥ãã°ã©ããŒã©ã®æåããè¡æ¶²éæïŒHDïŒæ£è
ã®é«è¡å§ãè
žå
现èç±æ¥ã®å°¿æ¯çŽ ã®å¶åŸ¡ã«å¯Ÿããæçãªå¹æãããããããšãçºè¡šãããŸããããŸããç ç©¶çµæãèžãŸããè¡æ¶²éææ£è
ã®è
žå
现èç°å¢ã®æ¹åãä»åŸãéèŠãªããŒããšãªãèŠè§£ã瀺ãããã
â ã«ã«ããŒæ ªåŒäŒç€Ÿ ããŒã±ãã£ã³ã°æ¬éšå
Œã·ãªã¢ã«éš éšé· æ±å£ è¡æ°ã®ã³ã¡ã³ã
ã«ã«ããŒæ ªåŒäŒç€Ÿã¯äŒæ¥ç念ãšããŠããç§ãã¡ã¯ãèªç¶ã®æµã¿ã倧åã«æŽ»ããããããããšæ¥œãããåµé ããŠã人ã
ã®å¥ãããªãããã«è²¢ç®ããŸããããæ²ããŠããŸããåœç€Ÿã§ã¯ããã«ãŒãå
¥ãã°ã©ããŒã©ã®ããŸããŸãªå¥åº·äŸ¡å€ã«ã€ããŠãé 倩å 倧åŠãšå
±åç ç©¶ã«åãçµãã§ãããŸããé 倩å 倧åŠãšã®å
±åç ç©¶ãéããŠãç§åŠçã«è§£æãããæ£ããæ
å ±ãçæŽ»è
ã®çæ§ã«å±ãããšãé¡ã£ãŠãããŸãããããŠãçæŽ»è
ã®çæ§ã®çè§£ãæ·±ãŸããå¥ãããªãããã«ç¹ããããšãå¿ããæãã§ãããŸãã
â ãé 倩å 倧åŠå»åŠéš è
èå
ç§åŠè¬åº§ äžç° èª äº éåžžå€è¬åž«ã®ã³ã¡ã³ã
çæŽ»ç¿æ
£ç
ã®èå»¶ãé«éœ¢åãèæ¯ã«ãæ
¢æ§è
èç
(CKD)æ£è
ã¯å¢å ã®äžéã蟿ããæ¬éŠã®CKDæ£è
æ°ã¯çŽ1330äžäººãšæšå®ãããæäººã®çŽ8人ã«1人ã¯CKDãšããããŠããŸããCKDã¯æ«æè
äžå
šãå¿è¡ç®¡çŸæ£ã®ãªã¹ã¯ã§ããããã®é²è¡ã黿¢ãé
å»¶ãããããšã¯è
æ©èœãçåœäºåŸãQOLæ¹åã«ã€ãªãããåœæ°ã®å¥åº·ãç¶æããäžã§å«ç·ã®èª²é¡ã§ãã
CKDã®çºçäºé²ãé²å±æå¶ã«ã¯é£äºçæ³ãçæŽ»ç¿æ
£ã®æ¹åããäžå¯æ¬ ã§ãããæžå¡©ã¯ããŸã äžååã§ãããŸããæ€ç©ç±æ¥ã®é£äºã®éèŠæ§ãçç®ãããŠããŸãããç¹ã«é²è¡ããCKDæ£è
ã§ã¯ãé£äºå¶éã®ãããã®æåãååã§ãªãé£ç©ç¹ç¶ã®æåãååã«è¡ããŠããŸããã
ãã«ãŒãå
¥ãã°ã©ããŒã©ã¯ãé£ç©ç¹ç¶ãå€ãå«ã¿ããŸãäžé£åœããã®é£å¡©ã0.5ïœãšå°ãªããããCKDæ£è
ã«æçšã§ããå¯èœæ§ã«çç®ããä»åã®æ€èšãè¡ããŸãããé²è¡ããCKDæ£è
ã察象ã«ããäžè¬çãªæé£ããã«ãŒãå
¥ãã°ã©ããŒã©ã«çœ®æãã詊éšã§ã¯ãæžå¡©ã«äŒŽãè¡å§æ°Žæºãäœäžããã°ããã§ãªããé£ç©ç¹ç¶ã®æåéã®å¢å ã«ãããè
žå
现èå¢ãæ¹åããCKDã§å€ãèŠããã䟿éç°åžžã®æ¹åãä¿ããããã«ã¯è
žå
现èç±æ¥ã®å°¿æ¯çŽ ç©è³ªã®è»œæžã芳å¯ãããå°æ¥ã®å¿è¡ç®¡ç
ã®çºçã®æå¶ã«å¯äžããå¯èœæ§ãèŠåºãããŸããã
åèæç®
Nagasawa H et al. Hypertens Res. 2024 Nov;47(11):3214-3224.
Nagasawa H et al. J Pharmacol Sci. 2021 Sep;147(1):132-137.
ãé 倩å 倧åŠå»åŠéš è
èå
ç§åŠè¬åº§ äžç° èª äº éåžžå€è¬åž«ãããã£ãŒã«ã
å³¶æ ¹å€§åŠå»åŠéš çµ±åè
çŸæ£å¶åŸ¡ç ç©¶ã»éçºã»ã³ã¿ãŒè
èåå¶åŸ¡éšé ç¹ä»»ææãé 倩å 倧åŠå»åŠéš è
èå
ç§åŠè¬åº§ éåžžå€è¬åž«ã
1995幎3æ ä¹
ç米倧åŠå»åŠéšåæ¥ãä¹
ç米倧åŠãçµãŠã2017幎4æïœ2024幎1æãŸã§é 倩å 倧åŠè
èå
ç§ã«æå±ã2024幎4æãããçŸè·ãå°éåéã¯ãæ
¢æ§è
èç
ã»é«è¡å§ãèåšé£é¢ãè
äžå
šé²å±æ©åºã®ç ç©¶ãé²ããŠããã
ïŒé 倩å 倧åŠãšã«ã«ããŒã®ç ç©¶çºè¡šã«ã€ããŠïŒ
ãè¡æ¶²éææ£è
ã«ããããã«ãŒãå
¥ãã°ã©ããŒã©æåãè¡å§äœäžããã³è
žå
现èå¢ã«åãŒã圱é¿ãã«é¢ããç ç©¶çµæãã¯ãããååŠäŒã§çºè¡šããææãååŠäŒèªã§æ²èŒãããè«æã®äžèЧãé²èЧã§ããã
https://www.calbee.co.jp/rd/joint/
â æé£æ¬ é£ã®å®æ
ãäŒããïŒã«ã«ããŒãæé£çœæžããçºè¡š
ã«ã«ããŒã¯ããæé£æ¬ é£ããªããããããšããæ³ãããã15ïœ89æ³ã®ç·å¥³10,304人ãå¯Ÿè±¡ã«æé£ãžã®è¡åãæèã調æ»ãã2025幎4æ1æ¥ïŒç«ïŒããããæé£çœæžããšããŠã100幎æé£ãããžã§ã¯ããµã€ããã«ãŠå
¬éäžã ã
ãæé£çœæžãã§ã¯ãæé£ã®å€§åãã«ã€ããŠæ¹ããŠäŒãããšãšãã«ãæ¬ é£=æé£ãæããªããæé£ãã£ã³ã»ã«ãã®å®æ
ãæµ®ã圫ãã«ããŠããã10,304 人ãžã®èª¿æ»ãããäžä»£ãã©ã€ãã¹ã¿ã€ã«ããšã«ç°ãªãæé£äºæ
ãæ©ã¿ãæããã«ãå°ãåºããã®ãã什åã®æé£å®æ
10 ã®ã€ã·ã¥ãŒãã ã
ãæé£çœæžãã§ã¯åã€ã·ã¥ãŒã®èæ¯ãšãªã詳现ãªããŒã¿ãå
¬éããèªèº«ãšè¿ãäžä»£ãã©ã€ãã¹ã¿ã€ã«ã®äººã
ãçŽé¢ããããæé£ã®èª²é¡ãèªèã§ããããæ§æããŠããããŸãæé£ã®å€§åãã«ã¯æ°ã¥ããŠããªããªãæããªãæ¹ã
ãžåããã³ã³ããã«ã©ããæŽããæé£ãç°¡åã«æãã³ãããæ é€å£«ã®æ°žåãã¡ããããäŒæããŠããã
ãæé£ãã£ã³ã»ã«ãå€ãã®ã¯è¥å¹Žå±€ãšäžäººæ®ãã
ã»ãŒæ¯æ¥æé£ãé£ã¹ã人ã®å²å㯠10 代ãã 20 代㧠10 ãã€ã³ã以äžããŠã³ã20 代ãæãæ¬ é£çãé«ããªã£ãããã®åŸã¯å¹Žéœ¢ãšãšãã«æ¬ é£çã¯äœäžããŠãããäžæ¹ãã©ã€ãã³ãŒã¹å¥ã§èŠããšãç¬èº«äžäººæ®ããã®çŸåœ¹äžä»£(~59 æ³)ã§æ¬ é£çãæãé«ããããã«åŠçã«ã€ããŠããäžäººæ®ããã®æ¬ é£çã®é«ãã
éç«ã€çµæãšãªã£ãã
ïŒããã«ã°ã©ãã®ãã©ã³ãã¹ããŒã¬ã³ãšã¹ããŒãã¡ã³ãïŒ
â ã«ã«ããŒæ ªåŒäŒç€Ÿ
â é 倩å 倧åŠ
â ITã©ã€ãããã¯
â ITã©ã€ããã㯠XïŒæ§TwitterïŒ
â ITã©ã€ããã㯠Facebook
â ITã©ã€ããã㯠YouTube
â ã«ã«ãã£ãŒã«é¢é£ããèšäºãèªã
ã»ãããã»ãã¶ãâäžçâãé£åã«ãå±ãïŒãåŒãããããäžçã®èãã¶ãããã¯ãŒã«ãããã æ¬§å·ç·šãæ°ååçºè¡šäŒ
ã»ãåç»ã¢ãªãBABYMONSTERãCreepy Nutsãçå°Ÿæ²èŒãšã³ã©ãïŒãSony Parkå±2025ãPart 2
ã»ããããªãïŒã¹ããŒãããããããªããã³ãããšã³ã©ãïŒè奜ãã«ããè奜ãã®ããã®çŠæã®ã¡ãã¥ãŒã販売ãž
ã»è¶
倧åããŒã¬ãŒãå ã
埩掻ïŒããŒã¬ãŒãã³ã°ããã©ããã· ã¶ã»ã¯ã³ããŠã³ããŒã
ã»æ¥æ¬æé«å³°ã®é£æãå²çè£ã§æ¥œãããïŒç¥æ¥œå å²çè£çŒè ç¥åãã¯ã©ãŠããã¡ã³ãã£ã³ã°ãéå§
7ä»¶ã®ã¬ã¹ããããŸã